PTHS Chromocell Therapeutics Corp

NYSE chromocell.com


$ 28.29 $ -2.44 (-7.94 %)    

Thursday, 20-Nov-2025 13:19:57 EST
QQQ $ 594.37 $ -17.61 (-2.88 %)
DIA $ 460.42 $ -6.28 (-1.35 %)
SPY $ 659.40 $ -13.50 (-2.01 %)
TLT $ 89.15 $ 0.16 (0.18 %)
GLD $ 373.19 $ -1.97 (-0.53 %)
$ 30.01
$ 30.00
$ 28.46 x 100
$ 30.14 x 20
$ 27.54 - $ 30.00
$ 5.10 - $ 54.29
37,955
na
91.88M
nm
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-13-2025 06-30-2025 10-Q
3 05-13-2025 03-31-2025 10-Q
4 03-27-2025 12-31-2024 10-K
5 11-13-2024 09-30-2024 10-Q
6 08-13-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 04-16-2024 12-31-2023 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Oppenheimer analyst Jeff Jones reiterates Pelthos Therapeutics (AMEX:PTHS) with a Outperform and raises the price target fro...

Core News & Articles

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.30) per share which missed the analyst consensus estimate of ...

Core News & Articles

Oppenheimer analyst Jeff Jones initiates coverage on Pelthos Therapeutics (AMEX:PTHS) with a Outperform rating and announces...

Core News & Articles

Pelthos Therapeutics (AMEX:PTHS) reported quarterly losses of $(5.38) per share which beat the analyst consensus estimate of $(...

 pelthos-therapeutics-launches-first-at-home-prescription-gel-for-highly-contagious-skin-disease

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little a...

Core News & Articles

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its partner Pelthos Therapeutics Inc. (NYSE:PTHS) has co...

Core News & Articles

- SEC Filing

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION